Push back against Mandatory COVID-19 vaccinations

National Billboard Campaign Underway

Push back against Mandatory COVID-19 vaccinations! Here is information based on publicly available sources – that you can use to write a letter or with which to seek the assistance of legal counsel:

 

  • There are No Licensed COVID-19 Vaccines in the U.S presently[1]. All COVID-19 vaccines are currently approved only as Emergency Use Authorized (EUAs) only – and “approval” does not mean “licensed.”[2]
  1. COVID-19 vaccines currently available, such as Moderna or Pfizer’s, are mRNA[3]
    1. What is an mRNA vaccine?[4]
    2. According to the CDC, contain “mRNA vaccines have strands of genetic material called mRNA inside a special coating. That coating protects the mRNA from enzymes in the body that would otherwise break it down. It also helps the mRNA enter the dendritic cells and macrophages in the lymph node near the vaccination site.” https://www.cdc.gov/vaccines/covid-19/hcp/mrna-vaccine-basics.html
    3. The Janssen Biotech, Inc, slightly different in using the viral vector to shuttle gene encoding, delivers ‘S Antigen DNA’… “The viral vector shuttles the gene encoding the S antigen into a human cell.”[5] And “the Oxford-AstraZeneca vaccine is based on the virus’s genetic instructions for building the spike protein. But unlike the Pfizer-BioNTech and Moderna vaccines, which store the instructions in single-stranded RNA, the Oxford vaccine uses double-stranded DNA.”[6]
  2.  All COVID-19 Vaccines are currently only approved as Emergency USE Authorizations (EUAs).
    1. What is an Emergency Use Authorization? “Under an EUA, FDA may allow the use of unapproved medical products, or unapproved uses of approved medical products in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when certain statutory criteria have been met, including that there are no adequate, approved, and available alternatives.”[7]
  3. There has never been, nor is there currently, a licensed mRNA vaccine in the United States[8].

 

  • There are No Long-Term Studies supporting Safety and Efficacy of EUA COVID-19 vaccines.
  1. Long-term side effects, severe or minor, are unknown because there are no PRIOR approved mRNA vaccines in the U.S.
  2. In 2020 the University of Pennsylvania did a mRNA Review, which can be summed up with this excerpt from the Review, that addresses the lack of sufficient data on mRNA vaccines in 2020, supporting the fact that all of the reliable data for both short-term and long-term trends will be based on the population who is now getting the COVID-19 vaccines[9]. This is the largest known experiment on Americans.
    1. While there is not sufficient data to statistically test these observations, a few trends are seen in the data.  First, the rate of adverse events and the rate of serious adverse events were higher after a subject’s second injection compared to the first one.  Second, subjects receiving higher doses of the vaccine reported more adverse events and more severe adverse events.  There is a possible trend towards a reduced rate of adverse events in older subjects than in younger ones.  There is not sufficient data to permit any conclusions about the comparative safety of specific vaccines.  While one study reported on mRNA influenza vaccines and another reported on a respiratory syncytial virus vaccine, there is not sufficient evidence to draw more generalized comparisons of the safety of mRNA vaccines compared to other types of vaccines.
  3. Your Option to Refuse is based on Federal law over EUAs[10]. No one has the right to mandate an EUA approved vaccine.
    1. Your Right to Informed Consent[11] is separate from the Option to Refuse, and is also based on Federal law over EUAs.
    2. The most recent relevant court decision in relation to an injunction application on an Emergency Authorized Vaccine (EUA) vaccine was Doe v. Rumsfeld, Civil Action No. 03-707, 2005 U.S. Dist. LEXIS 5573, *2-3, 2005 WL 1124589, where the United States District Court for the District of Columbia required that the EUA anthrax vaccine be only administered in the military on a voluntary basis “pursuant to the terms of a lawful emergency use authorization (“EUA”) pursuant to section 564 of the Federal Food, Drug, and Cosmetic Act.”  This decision, as the earlier decision in Doe v. Rumsfeld, 297 F. Supp. 2d 119 also found the EUA could not be mandated; recognizing the option to refuse under federal law governing EUAs.
    3. To be clear, the EEOC’s guidance updated on May 28, 2021, related to language suggesting that vaccines may be “required” by employers, only states that “federal EEO laws do not prevent an employer from requiring all employees physically entering the workplace to be vaccinated…”[21]   This is called a word game or word salad.  This is a limited statement that does not include other federal law, specifically 21 USCS § 360bbb-3, discussed above, which requires that EUA’s are administered with the option to refuse and the right to informed consent, which requires both the benefits and the negatives of an EUA vaccine.
    4. There is Potential Liability on Employers or Universities that Mandate Vaccines if an Employee or Student suffers any Side Effects or Death from a mandatory EUA vaccine.
      1. It is a violation of your privacy rights to be forced to declare whether you have been vaccinated or not.  When a Virtue Hunter seeks this information, remind them of privacy rights of your own medical information, also known as PHI and PII[12]
      2. Ask about all updates on safety because you have the right to informed consent. For example, the CDC has recently put out information in April of 2021on reports of Myocarditis following mRNA vaccines.[13]
      3. And most recently, Luc Montagnier, a French virologist and recipient of the 2008 Nobel Prize in Medicine for his discovery of the human immunodeficiency virus (HIV), has recently exposed the dangers of the COVID-19 vaccines. Montagnier discussed the issue in an interview with Pierre Barnérias of Hold-Up Media earlier this month, which was exclusively translated from French into English for RAIR Foundation USA. The vaccines don’t stop the virus, argues the prominent virologist, they do the opposite – they “feed the virus,” and facilitate its development into stronger and more transmittable variants. These new virus variants will be more resistant to vaccination and may cause more health implications than their “original” versions.[14]
      4. On April 20, 2021 OSHA issued guidance this week that says, “If you require your employees to be vaccinated as a condition of employment (i.e., for work-related reasons), then any adverse reaction to the COVID-19 vaccine is work-related. The adverse reaction is recordable if it is a new case under 29 CFR 1904.6 and meets one or more of the general recording criteria in 29 CFR 1904.7.”
      5. Now, however, due to Administration virtue signaling, the language from OSHA appears to have been updated to state:Are adverse reactions to the COVID-19 vaccine recordable on the OSHA recordkeeping log?DOL and OSHA, as well as other federal agencies, are working diligently to encourage COVID-19 vaccinations. OSHA does not wish to have any appearance of discouraging workers from receiving COVID-19 vaccination, and also does not wish to disincentivize employers’ vaccination efforts. As a result, OSHA will not enforce 29 CFR 1904’s recording requirements to require any employers to record worker side effects from COVID-19 vaccination through May 2022. We will reevaluate the agency’s position at that time to determine the best course of action moving forward.
      6. Are they arbitrarily changing the law – to fit virtue signaling…? The question would then become, can an agency change enforcement of a regulation without following the APA and putting out notice of a rule change?
      7. Does your employer or university want to find out what the lack of informed consent or making available the option to refuse or the mandated disclosure of private health information means in civil litigation when there is injury after mandating a EUA vaccine, or in worker’s compensation court depending on the coverage?
    5. Preliminary Research from the National Institutes of Health shows Immunity for those of who have had COVID-19.
      1. No studies yet exist on the long-term impact on someone getting an EUA COVID-19 Vaccine who has had COVID-19.
      2. CDC appears to ignore research such as the NIH study in early 2021[15] ,[16] which is based on more recent research than the authorizations that the EUA approvals were based on for the current EUAs, when the CDC issued its guidance on recommended vaccinations. Preliminary Research shows those who have had Covid-19 do have T-cells that protect them from reinfection, which is greater than the six months some were led to believe.Despite this, the CDC recommends vaccination “Even if you have already recovered from COVID-19, it is possible-although rare-that you could be infected with the virus that causes COVID-19 again…”[17] And it appears the CDC is ignoring its own medical definition of immunity:  “Immunity: Protection from an infectious disease. If you are immune to a disease, you can be exposed to it without becoming infected.”[18] – which obviously indicates that you are immune when you have already been infected.
      3. Children under 16 show 0 risk of infection or getting symptomatic from COVID-19.[19]
      4. And this is without getting to the question of currently available treatment options for COVID-19 and whether there is still a basis for an EUA.[20]

 

 

[1] “There are currently no licensed mRNA vaccines in the United States.” https://www.cdc.gov/vaccines/covid-19/hcp/mrna-vaccine-basics.html.

 

[2] The most updated list of licensed vaccines in the U.S. is at FDA.gov.  https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states

 

[3] Moderna “The vaccine contains a nucleoside-modified messenger RNA encoding the viral spike (S) glycoprotein of SARS-CoV-2 formulated in lipid particles.  It is an investigational vaccine not licensed for any indication.”    See FDA letter 2/25/01 to Moderna granting “Emergency Use Authorization (EUA)”.  

 

Pfizer Bio-NTech Covid-19 vaccine:  “The vaccine contains a nucleocide-modified messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2 formulated in lipid particles.  It is an investigational vaccine not licensed for any indication.”    See FDA letter 2/25/01 to Pfizer Bio-NTech granting “Emergency Use Authorization (EUA).”

[4] mRNA Vaccines Are New, But Not Unknown   There are currently no licensed mRNA vaccines in the United States. However, researchers have been studying them for decades.  https://www.cdc.gov/vaccines/covid-19/hcp/mrna-vaccine-basics.html

[5] Janssen Biotech, Inc.https://www.janssencovid19vaccine.com/hcp/how-its-designed.html

… “The vaccine contains a recombinant, replication-incompetent human adenovirus serotype 26 (AD26) vector, encoding the SARS-CoV-2 viral spike (S) glycoprotein, stabilized in its pre-fusion form.  It is an investigational vaccine not licensed for any indication.”   See FDA letter 2/27/01 to Janssen Biotech, Inc. granting “Emergency Use Authorization (EUA).”

[6] https://www.nytimes.com/interactive/2020/health/oxford-astrazeneca-covid-19-vaccine.html

 

[7] https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained

[8] mRNA Vaccines Are New, But Not Unknown   There are currently no licensed mRNA vaccines in the United States. However, researchers have been studying them for decades.  https://www.cdc.gov/vaccines/covid-19/hcp/mrna-vaccine-basics.html

[9]  ADVERSE EFFECTS OF MESSENGER RNA VACCINES An Evidence Review from the Penn Medicine Center for Evidence-based, Practice December 2020, director Nikhil K. Mull, MD  (CEP) Lead analyst: Matthew D. Mitchell, PhD  (CEP)Clinical review Patrick J. Brennan, MD. (CMO)http://www.uphs.upenn.edu/cep/COVID/mRNA%20vaccine%20review%20final.pdf at p.11, Primary Studies.

 

[10] According to the Section 564 of the Federal Food, Drug, and Cosmetic Act, a lawful application of the terms of a lawful emergency use authorization (“EUA”) pursuant includes (e)(1)(A)(i)(III):

(III) of the option to accept or refuse administration of the product, of the consequences, if any, of refusing administration of the product, and of the alternatives to the product that are available and of their benefits and risks.

21 USCS § 360bbb-3

https://www.law.cornell.edu/uscode/text/21/360bbb-3

 

[11] (II) of the significant known and potential benefits and risks of such use, and of the extent to which such benefits and risks are unknown.

 

21 USCS § 360bbb-3

https://www.law.cornell.edu/uscode/text/21/360bbb-3

 

See also the FDA’s guidance on the right to informed consent and the option to refuse:

How will vaccine recipients be informed about the benefits and risks of any vaccine that receives an EUA?

FDA must ensure that recipients of the vaccine under an EUA are informed, to the extent practicable given the applicable circumstances, that FDA has authorized the emergency use of the vaccine, of the known and potential benefits and risks, the extent to which such benefits and risks are unknown, that they have the option to accept or refuse the vaccine, and of any available alternatives to the product. Typically, this information is communicated in a patient “fact sheet.” The FDA posts these fact sheets on our website.

https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained

 

 

[12] PHI is an acronym of Protected Health Information, while PII is an acronym of Personally Identifiable Information — while you can always waive your privacy rights, you have the right to determine your own release of private medical information.  https://www.hipaajournal.com/what-is-considered-phi/

[13] On May 17, 2021, the CDC stated: The VaST session on May 17, 2021, included several presentations on myocarditis following mRNA vaccines, from the Department of Defense (DoD), the Vaccine Adverse Event Reporting System (VAERS), and Vaccine Safety Datalink (VSD). There were also brief updates from the Veteran’s Administration (VA) and the Clinical Immunization Safety Assessment (CISA) groups about their plans for future investigation of myocarditis.  COVID-19 VaST Work Group Technical Report – May 17, 2021.  https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm?fbclid=IwAR2-muRM3tB3uBdbTrmKwH1NdaBx6PpZo2kxotNwkUXlnbZXCwSRP2OmqsI

[14] Nobel Prize Winner Warns Vaccines Facilitate Development of Deadlier COVID Variants, Urges Public to Reject Jabs, by Veronika Kyrylenko, The New American, May 20, 2021: https://thenewamerican.com/french-nobel-prize-winner-warns-vaccines-facilitate-development-of-deadlier-covid-variants-urges-the-public-to-reject-jabs/

 

[15] CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants – PubMed

https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F33594378%2F&data=04%7C01%7C%7Cf496c029c7a546320c2508d8f90cf35b%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C637533181300658523%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=daj%2FesDTdKPA8V669M48HmIOBTkXVmFrGKu5pqJZAZE%3D&reserved=0

 

[16] Lasting immunity found after recovery from COVID-19, National Institutes of Health, January 26, 2021 https://www.nih.gov/news-events/nih-research-matters/lasting-immunity-found-after-recovery-covid-19?fbclid=IwAR0NvW6PWXlK4xIf7yTulxhYagh6qAaSL4cZbVCJXmjuON-q4Lsz6A9Wa24

 

[17] Frequently Asked Questions about COVID-19 Vaccination, “If I have already had COVID-19 and recovered, do I still need to get vaccinated with a COVID-19 vaccination? https://www.cdc.gov/coronavirus/2019-ncov/vaccines/faq.html

 

[18] CDC, Definition of Terms https://www.cdc.gov/vaccines/vac-gen/imz-basics.htm#:~:text=Definition%20of%20Terms,-Let’s%20start%20by&text=Vaccine%3A%20A%20product%20that%20stimulates,or%20sprayed%20into%20the%20nose.

 

[19] See the Petition for a Temporary Restraining Order filed this week in the U.S. District Court for the Northern District of Alabama by America’s FrontLine Doctors, 2:21-cv-00702, CLM.

[20] https://finance.yahoo.com/news/hydroxychloroquine-90-percent-chance-helping-155637974.html

 

[21] “The federal EEO laws do not prevent an employer from requiring all employees physically entering the workplace to be vaccinated for COVID-19, subject to the reasonable accommodation provisions of Title VII and the ADA and other EEO considerations discussed below.  These principles apply if an employee gets the vaccine in the community or from the employer.”  https://www.eeoc.gov/wysk/what-you-should-know-about-covid-19-and-ada-rehabilitation-act-and-other-eeo-laws

Defending The Republic - All rights reserved.


Mobile Messaging Terms & Conditions and Mobile Messaging Privacy Policy

Effective Date: May 21st, 2021

Defending The Republic, INC (hereinafter “We,” “Us,” “Our”) is offering a mobile messaging program (the “Program”), which you agree to use and participate in subject to these Mobile Messaging Terms and Conditions and Privacy Policy (the “Terms”). By opting into or participating in any of our Programs, you accept and agree to these Terms, including, without limitation, your agreement to resolve any disputes with us through binding, individual-only arbitration, as detailed in the “Dispute Resolution” section below. These Terms are limited to the Program and are not intended to modify other terms & conditions or privacy policy(ies) that may govern the relationship between you and Us in other contexts.

(Read more) Modification of Terms: We reserve the right to revise these Terms from time to time. If we do revise these Terms, the revised terms will supersede prior revisions. Unless we say otherwise, revisions will be effective upon the effective date indicated at the top of these Terms. Any updates to these Terms shall be communicated to you by mobile message with a link to the updated Terms. Your continued participation in the Program after receiving notice of the updated Terms constitutes your acceptance of any revisions. If you do not agree to the revisions, you must opt out of the Program.

User Opt In: The Program allows users to receive mobile messages by affirmatively opting into the Program. Regardless of the opt-in method you utilized to join the Program, you agree that these Terms apply to your participation in the Program. By participating in the Program, you agree to receive autodialed or prerecorded marketing mobile messages at the phone number associated with your opt-in, and you understand that consent is not required to make any purchase from Us. While you consent to receive messages sent using an autodialer, the foregoing shall not be interpreted to suggest or imply that any or all of Our mobile messages are sent using an automatic telephone dialing system (“ATDS” or “autodialer”). Message and data rates may apply.

User Opt Out: If you do not wish to continue participating in the Program or no longer agree to these Terms, you agree to reply “STOP,” “QUIT,” “END,” “CANCEL,” “UNSUBSCRIBE,” or “STOP ALL” to any mobile message from Us in order to opt out of the Program. You may receive an additional mobile message confirming your decision to opt out. You understand and agree that the foregoing options are the only reasonable methods of opting out. You also understand and agree that any other method of opting out, including, but not limited to, texting words other than those set forth above or verbally requesting one of our employees to remove you from our list is not a reasonable means of opting out.

T-Mobile and AT&T provide daily files for phone numbers that have deactivated from their network or been ported from one carrier to another. We proactively opt-out deactivated numbers from our subscription list.

Duty to Notify and Indemnify: If at any time you intend to stop using the mobile telephone number used to subscribe to the Program, including canceling your service plan or selling or transferring the phone number to another party, you agree that you will complete the User Opt Out process set forth above prior to ending your use of the mobile telephone number. You understand and agree that your agreement to do so is a material part of these Terms. You further agree that, if you discontinue the use of your mobile telephone number without notifying Us of such change, you agree that you will be responsible for all costs (including attorneys’ fees) and liabilities incurred by Us, or any party that assists in the delivery of the mobile messages, as a result of claims brought by the individual(s) who is later assigned that mobile telephone number. This duty and agreement shall survive any cancellation or termination of your agreement to participate in any of our Programs.

YOU AGREE THAT YOU SHALL INDEMNIFY, DEFEND, AND HOLD US, OUR AGENTS, AND ANY THIRD-PARTY SERVICE PROVIDER WE USE TO SEND TEXT MESSAGES HARMLESS FROM ANY CLAIM OR LIABILITY RESULTING FROM YOUR FAILURE TO NOTIFY US OF A CHANGE IN THE INFORMATION YOU HAVE PROVIDED, INCLUDING, BUT NOT LIMITED TO, ANY CLAIM OR LIABILITY UNDER THE TELEPHONE CONSUMER PROTECTION ACT, 47 U.S.C. § 227, et seq., OR SIMILAR STATE AND FEDERAL LAWS, AND ANY REGULATIONS PROMULGATED THEREUNDER RESULTING FROM US ATTEMPTING TO CONTACT YOU AT THE MOBILE TELEPHONE NUMBER YOU PROVIDED.

Program Description: Without limiting the scope of the Program, users that opt into the Program can expect to receive messages concerning our commercial activities and your relationship with us, including, but not limited to, messages concerning product advertisements and promotions of any kind from us.

Cost and Frequency: Message and data rates may apply. The Program involves recurring mobile messages, and additional mobile messages may be sent periodically based on your interaction with Us.

Support Instructions: For support regarding the Program, text “HELP” to 90046 or email Us at support@defendingtherepublic.org. Please note that the use of this email address is not an acceptable method of opting out of the program. Opt outs must be submitted in accordance with the User Opt Out procedures set forth above.

MMS Disclosure: The Program will send SMS TMs (terminating messages) if your mobile device does not support MMS messaging.

Our Disclaimer of Warranty: The Program is offered on an “as-is” basis and may not be available in all areas at all times and may not continue to work in the event of product, software, coverage, or other changes made by your wireless carrier. We will not be liable for any delays or failures in the receipt of any mobile messages connected with the Program. Delivery of mobile messages is subject to effective transmission from your wireless service provider/network operator, and is outside of Our control. T-Mobile is not liable for delayed or undelivered mobile messages.

Age Restriction: You may not use or engage with the Program if you are under thirteen (13) years of age. If you use or engage with the Program and are between the ages of thirteen (13) and eighteen (18) years of age, you must have your parent’s or legal guardian’s permission to do so. By using or engaging with the Platform, you acknowledge and agree that you are not under the age of thirteen (13), are between the ages of thirteen (13) and eighteen (18) and have your parent’s or legal guardian’s permission to use or engage with the Program, or are of adult age in your jurisdiction. By using or engaging with the Program, you also acknowledge and agree that you are permitted by your jurisdiction’s applicable law to use and/or engage with the Program.

Truthful and Accurate Information: When you complete forms online or otherwise provide Us information in connection with the Program, you agree to provide accurate, complete, and true information. You agree not to use a false or misleading name or a name that you are not authorized to use. If, in Our sole discretion, We believe that any such information is untrue, inaccurate, or incomplete, or you have opted into the Program for an ulterior purpose, We may refuse you access to the Program and pursue any appropriate legal remedies.

Our Warranty: We will not be liable for any delays or failures in the receipt of any mobile messages connected with this Program. Delivery of mobile messages is subject to effective transmission from your wireless service provider/network operator, and is outside of Our control. T-Mobile is not liable for delayed or undelivered mobile messages.

Mobile Messaging Privacy Policy: We respect your privacy. This Mobile Messaging Privacy Policy describes any personal information that We collect or receive when you choose to participate in the Program, how We use or disclose your information, and your rights related to your personal information. This Mobile Messaging Privacy Policy applies to all personal information collected, used, or shared by us when you opt-in to the Program and is strictly limited to the Program and has no effect on any other privacy policy(ies) that may govern the relationship between you and Us in other contexts. Please contact Us if you have any questions about the information in this Privacy Policy.

Information We Collect and How We Use It: The personal information We may collect, includes your name, phone number, email address and certain marketing preferences. We may also collect data with respect to confirmation that a message has been delivered to you, confirmation that you have read a message, and related information. We may use the information for the following business purposes: (1) provide the Program and related customer service; (2) deliver information about Our products, services and promotions, (3) improve the Program and services, (4) prevent fraud and comply with law, and (5) protect the security of Our systems. We may combine the personal information We obtain through your participation in the Program with offline or other online personal information We retain about you.

When We Share Your Information: WE DO NOT SELL, RENT, LOAN, TRADE, LEASE OR OTHERWISE TRANSFER FOR PROFIT ANY PHONE NUMBERS OR PERSONAL INFORMATION COLLECTED OR RECEIVED THROUGH THE PROGRAM TO ANY THIRD PARTY. However, We may share your personal information with the third-party text messaging platform provider or other trusted service partners as may be necessary to send you messages under the Program and these Terms. We reserve the right at all times to disclose any information as necessary to satisfy any law, regulation or governmental request, to avoid liability, or to protect Our rights or property.

Contact Us: To exercise any of your rights related to your personal information, please contact us using one of the following methods:

Visit us at https://DefendingTheRepublic.org; Send us an email at support@defendingtherepublic.org; or Write to us at 10130 Northlake Blvd, 214-342 West Palm Beach, FL 33412. California Residents. Beginning January 1, 2020, if You are a California resident, as defined in Section 17014 of Title 18 of the California Code of Regulations, You have certain rights with regard to your personal information. This section describes those rights and explains how to exercise those rights.

Access to Information. You have the right to request that We disclose certain information to you about Our collection and use of your personal information over the past 12 months. Upon receipt of a verifiable request, we will provide you access to personal information We have collected about you or disclose to you the categories of personal information We have collected, the categories of sources from which We obtained that information, and how We have used or shared that information.

Right to Request Deletion. You also have the right to request that We delete any of your personal information that We collected from you and retained, subject to certain exceptions as allowable by law. You understand that We may deny your deletion request as provided by law, including, but not limited to, retaining the information if it is necessary for Us to:

Complete the transaction for which We collected the personal information, provide a good or service that you requested, take actions reasonably anticipated within the context of Our ongoing business relationship with you, or otherwise perform Our contract with you; Detect security incidents, protect against malicious, deceptive, fraudulent, or illegal activity, or prosecute those responsible for such activities; Debug products or identify and repair errors that impair existing intended functionality; Comply with a legal obligation, including, but not limited to, preserving evidence demonstrates our compliance with the Telephone Consumer Protection Act (“TCPA”) during the statute of limitations period applicable to the TCPA; and/or Make other internal and lawful uses of that information that are compatible with the context in which you provided it. To exercise any of your rights related to your personal information, please contact us using one of the methods indicated in the “Contact Us” section above.

Dispute Resolution: In the event that there is a dispute, claim, or controversy between you and Us, or between you and our third-party text messaging platform provider, or between you and any other third-party service provider acting on Our behalf to transmit the mobile messages related to the Program Description set forth above, arising out of or relating to federal or state statutory claims, common law claims, these Terms, or the breach, termination, enforcement, interpretation, or validity thereof, including, but not limited to, the determination of the scope or applicability of this agreement to arbitrate, such dispute, claim, or controversy will be, to the fullest extent permitted by law, determined by arbitration in West Palm Beach, Florida before one arbitrator.

The parties agree to submit the dispute to binding arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”) then in effect. Except as otherwise provided herein, the arbitrator shall apply the substantive laws of the Federal Judicial Circuit in which Our principal place of business is located, without regard to its conflict of laws rules. Within ten (10) calendar days after the arbitration demand is served upon a party, the parties must jointly select an arbitrator with at least five (5) years’ experience in that capacity and who has knowledge of and experience with the subject matter of the dispute. If the parties do not agree on an arbitrator within ten (10) calendar days, either party may petition the AAA to appoint an arbitrator, who must satisfy the same experience requirement. In the event of a dispute, the arbitrator shall decide the enforceability and interpretation of this arbitration agreement in accordance with the Federal Arbitration Act (“FAA”). The parties also agree that the AAA’s rules governing Emergency Measures of Protection shall apply in lieu of seeking emergency injunctive relief from a court. The decision of the arbitrator shall be final and binding, and no party shall have rights of appeal except for those provided in section 10 of the FAA. Each party shall bear its share of the fees paid for the arbitrator and the administration of the arbitration; however, the arbitrator shall have the power to order one party to pay all or any portion of such fees as part of a well-reasoned decision. The parties agree that the arbitrator shall have the authority to award attorneys’ fees only to the extent expressly authorized by statute or contract. The arbitrator shall have no authority to award punitive damages and each party hereby waives any right to seek or recover punitive damages with respect to any dispute resolved by arbitration. The parties agree to arbitrate solely on an individual basis, and this agreement does not permit class arbitration or any claims brought as a plaintiff or class member in any class or representative arbitration proceeding. Except as may be required by law, neither a party nor the arbitrator may disclose the existence, content, or results, of any arbitration without the prior written consent of both parties, unless to protect or pursue a legal right. If any term or provision of this Section is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other term or provision of this Section or invalidate or render unenforceable such term or provision in any other jurisdiction. If for any reason a dispute proceeds in court rather than in arbitration, the parties hereby waive any right to a jury trial. This arbitration provision shall survive any cancellation or termination of your agreement to participate in any of our Programs.

Miscellaneous: You warrant and represent to Us that you have all necessary rights, power, and authority to agree to these Terms and perform your obligations hereunder, and nothing contained in this Agreement or in the performance of such obligations will place you in breach of any other contract or obligation. The failure of either party to exercise in any respect any right provided for herein will not be deemed a waiver of any further rights hereunder. If any provision of these Terms is found to be unenforceable or invalid, that provision will be limited or eliminated to the minimum extent necessary so that this Agreement will otherwise remain in full force and effect and enforceable. Any new features, changes, updates, or improvements of the Program shall be subject to these Terms unless explicitly stated otherwise in writing.